STUDY. the most frequent autoimmune blistering skin disease. 1,2 It is most common in
|
|
- Garry Park
- 6 years ago
- Views:
Transcription
1 STUDY Prediction of Survival for Patients With Bullous Pemphigoid A Prospective Study Pascal Joly, MD, PhD; Jacques Benichou, MD, PhD; Catherine Lok, MD, PhD; Marie France Hellot, ScD; Philippe Saiag, MD, PhD; Emmanuelle Tancrede-Bohin, MD; Bruno Sassolas, MD; Bruno Labeille, MD; Marie Sylvie Doutre, MD, PhD; Isabelle Gorin, MD; Christine Pauwels, MD; Olivier Chosidow, MD, PhD; Frédéric Caux, MD, PhD; Eric Estève, MD; Yves Dutronc, MD; Michèle Sigal, MD; Catherine Prost, MD, PhD; Hervé Maillard, MD; Jean Claude Guillaume, MD; Jean Claude Roujeau, MD Objective: To identify the prognostic factors of bullous pemphigoid (BP). Design: Prospective study of patients with BP included in a randomized, controlled trial. Setting: Twenty dermatology departments in France. Patients: One hundred seventy patients with BP initially treated with a 40-g/d dosage of clobetasol propionate cream (testing sample) and 171 patients initially treated with oral corticosteroids at a dosage of 0.5 or of mg/kg per day, depending on the extent of BP (validation samples). Main Outcome Measures: The end point was overall survival during the first year after BP diagnosis. From the testing sample, associations of clinical and biological variables with overall survival were assessed using univariate and multivariate analyses. Selected predictors were included in a prognostic model. To verify that these predictors were not dependent on the treatment used, the model was then validated independently on the 2 series of BP patients treated with oral corticosteroids. Results: Median age of the BP patients included in the testing sample was 83 years. The 1-year Kaplan-Meier survival rate was 74%. From univariate analysis, the main deleterious predictors were demographic factors (ie, older age and female sex), associated medical conditions (ie, cardiac insufficiency, history of stroke, and dementia), and low Karnofsky score, which is a measure of the patient s general condition. No factors directly related to BP, in particular extent of cutaneous lesions, were shown to be related to the patients prognosis. From multivariate analysis, only older age (P=.02) and low Karnofsky score (P.001) appeared independently predictive of death. From the Cox model including these 2 predictors, the predicted 1-year survival rates were 90% (95% confidence interval [CI], 85%-96%) for patients 83 years or younger with Karnofsky score greater than 40, 79% (95% CI, 69%-90%) for patients older than 83 years with Karnofsky score greater than 40, 65% (95% CI, 50%- 86%) for patients 83 years or younger with Karnofsky score of 40 or less, and 38% (95% CI, 26%-57%) for patients older than 83 years with Karnofsky score of 40 or less. Kaplan-Meier survival distributions of patients from the validation samples appeared clearly separated according to these 4 categories and were in close agreement with corresponding predicted 1-year survival rates obtained from the testing sample. Conclusions: The prognosis of patients with BP is influenced by age and Karnofsky score. These predictors are easy to use and should facilitate the management of BP. Arch Dermatol. 2005;141: Author Affiliations are listed at the end of this article. Financial Disclosure: None. BULLOUS PEMPHIGOID (BP) IS the most frequent autoimmune blistering skin disease. 1,2 It is most common in elderly patients. 3-6 Until recently, systemic corticosteroids have been considered the standard treatment of BP. 3,7 The prognosis of BP is severe because the 1-year mortality rate has been reported to range from 25% to 40% in recent series. 3,4,8-12 Two recent retrospective studies 3,12 have identified older age as independently predictive of death, but other independent prognostic factors identified by these 2 studies were in stark contrast. Indeed, the study by Roujeau et al 3 found extensive (relative to moderate) disease form, poor general condition, and female sex to be independently predictive of death, whereas the study by Rzany et al 12 identified high doses of oral corticosteroids at hospital discharge and a low serum albumin level as independent prognostic factors of death. It is likely that the 691
2 retrospective nature of these 2 studies and the absence of control of treatment modalities were responsible for these discrepancies. Given the large number of treatments proposed in the literature for patients with BP (hereafter referred to as BP patients) and the high risk of severe adverse effects with treatments such as oral corticosteroids or immunosuppressive drugs in these patients, who are mostly elderly, it appears critical to adapt treatment aggressiveness to individual patient prognosis To disentangle the conflicting findings of the 2 previous retrospective studies, we undertook a prospective prognostic study of BP using a large series of patients treated in a homogeneous manner. Patients in our series were included in a recently reported randomized clinical trial that compared oral and topical corticosteroids in the treatment of BP patients. 11 This randomized trial demonstrated that high-potency topical corticosteroids were safer and more effective than high doses of oral corticosteroids for controlling extensive BP. Half of the patients in this trial were treated with topical corticosteroids. Using data from these patients, prognostic factors of overall survival were identified and a prognostic regression model was developed. This model was then validated independently on 2 series of patients who received various dosages of oral corticosteroids. METHODS PATIENTS This prospective multicenter study was conducted in 20 departments of dermatology in France. More details can be found in Joly et al. 11 Briefly, consecutive patients with incident BP were recruited if the following inclusion criteria were met: (1) clinical features suggestive of BP 6 ; (2) the typical histological pattern of BP, including a subepidermal blister on a skin biopsy specimen 24 ; and (3) linear deposits of IgG and/or C3 along the basement membrane zone as shown on results of direct immunofluorescence. 25,26 Patients were randomly assigned to receive topical or oral corticosteroids. The study was approved by the ethics committee of Seine Maritime, and written informed consent was obtained for each patient. Prognostic factors of overall survival were determined from the data of patients randomized to receive topical corticosteroids (testing sample). These patients were treated initially with a 40-g/d dosage of clobetasol propionate cream that was applied twice daily on the entire body surface until 15 days after disease control. Disease control was defined as the absence of new bullae for 3 consecutive days. Dosages of clobetasol propionate cream were then gradually tapered to 20 g/d for 1 month, 10 g/d for 2 months, 10 g every other day for 4 months, and finally 10 g twice a week for 4 months. Relapse was defined as the occurrence of at least 3 new bullae daily for 3 consecutive days during treatment. Patients who experienced relapse during the period when treatment dosages were being reduced had their dosages increased to the previous level that had permitted disease control. Treatment was stopped after 12 months. External validation of the prognostic factors and corresponding prognostic model was carried out from the data of 2 series of patients randomized to receive oral corticosteroids (validation samples). Patients with moderate BP (ie, 10 new bullae daily) received oral prednisone (Cortancyl; Roussel Laboratories, Paris, France) at the initial daily dosage of 0.5 mg/kg of body weight, whereas those with extensive BP (ie, 10 new bullae daily) received twice that dosage initially (ie, 1 mg/kg of body weight per day). The initial dosage was maintained for 15 days after disease control had been attained. Thereafter, it was reduced by 15% every 3 weeks. As for patients in the testing sample, the dosage was increased to the previous level that had permitted disease control if a relapse occurred, and treatment was stopped after 12 months. In both the testing and validation samples, other therapy that might affect BP activity was avoided throughout the 12-month study period, and investigators stopped treatment if a life-threatening adverse effect occurred. BASELINE AND FOLLOW-UP MEASUREMENT At baseline, each patient underwent complete physical examination. The daily number of new bullae during the 3 days before the initiation of therapy was noted by a nurse. The following clinical findings were recorded: delay since onset of initial cutaneous lesions, type and localization of cutaneous lesions, pruritus, Karnofsky score, personal history of cardiovascular disease (eg, high blood pressure, cardiac insufficiency, angina pectoris, ischemia, cardiac arrhythmia, arteriosclerosis of the leg, deep vein thrombosis, or pulmonary embolism), neurologic disorder (eg, stroke, dementia, Parkinson disease, or other), psychiatric disorder, hepatic and/or digestive disease (eg, diverticulosis, cirrhosis, gastric ulcer, or cholelithiasis), chronic lung condition, diabetes mellitus, malignancy, endocrine disorder, and urologic disease. The Karnofsky score is a measure of the patient s general condition and degree of autonomy on a scale ranging from 0 to 100, with higher scores indicating better condition and greater autonomy. 27 Blood eosinophil counts and titers of serum anti membrane zone antibodies were determined by indirect immunofluorescence on normal human skin and recorded. Follow-up visits were planned on days 7, 14, 21, 30, 90, 180, and 360. The date of any relapse that occurred and the date and cause of death in any patients who had died were recorded. Because of the high 1-year mortality rate reported in recent series, follow-up was planned to last 12 months only. STATISTICAL ANALYSIS The end point of this prognostic study was overall survival during the first year after the diagnosis of BP. To select determinants of overall survival, the testing sample was used. Associations between baseline variables and overall survival were studied using univariate and multivariate analyses. In univariate analysis, the prognostic significance on overall survival was assessed using the log-rank test for categorical variables and the Cox proportional hazards regression model for continuous variables. Relative risks (RRs) and corresponding 95% confidence intervals (CIs) were estimated using the Cox proportional hazards regression model for categorical and continuous variables. The RRs per unit were estimated for continuous variables. Variables that appeared separately associated with overall survival at the P.15 level were further retained for multivariate analysis. Stepwise Cox regression was used to select prognostic variables independently associated with overall survival at the P.05 level. Adjusted RRs and corresponding 95% CIs were estimated for these variables. Observed distributions of overall survival according to levels of these variables (alone or in combination) were estimated using the Kaplan-Meier method. Predicted distributions of survival were obtained from the Cox model based estimates of empirical cumulative hazard functions. 28 The multivariate coefficient of determination (R 2 )ofxu and O Quigley was used to assess the proportion of variation explained by the variables included in these models. 29 We used SAS statistical software (version 8.02; SAS Institute Inc, Cary, 692
3 NC) for all other analyses. Unless otherwise indicated, continuous variables are expressed as mean±sd. RESULTS BASELINE CHARACTERISTICS One hundred seventy patients (69 men and 101 women) were randomized to receive topical corticosteroids and thus were included in the testing sample of this prognostic study. Their mean age was 81±10 years (median age, 83 years). Their mean Karnofsky score was 64±25 (median score, 60). The mean number of daily new blisters was 29±46. One hundred eleven (73%) of 153 patients were determined by indirect immunofluorescence to have circulating anti basement membrane zone antibodies, and the mean number of blood eosinophils was 1480±1450 cells/µl. FOLLOW-UP AND OVERALL OUTCOME Control of BP was achieved in all but 1 patient (169/170 [99%]) by day 21. Sixty-one patients (36%) experienced relapse during the study after a mean of 185±122 days. During the 1-year follow-up, 45 patients (26%) died. The primary cause of death was determined in 34 cases. The main causes were sepsis (in 10 patients, including 8 with pneumonia), cardiovascular disease (in 9), and stroke (in 5). The 1-year Kaplan-Meier overall survival rate was 73% (95% CI, 66%-80%) (Figure 1). Among the surviving patients, the mean follow-up time was 360±105 days (median, 365 days; 25th and 75th percentiles, 360 and 365 days, respectively). SEPARATE PROGNOSTIC FACTORS FROM UNIVARIATE ANALYSIS From univariate analysis, older age was strongly associated with shorter survival, whether age was dichotomized (eg, 83 vs 83 years) or coded as a continuous variable (Table 1). For example, the RR of death was estimated at 3.1 (95% CI, ; P.001) and the 1-year Kaplan-Meier overall survival was estimated at 61% for patients older than 83 years (85% for patients 83 years) (Figure 2A). We retained the dichotomous coding ( 83 and 83 years) for further analysis because the median age in this series was 83 years. Female sex was likewise associated with poorer survival. Poor general condition, as reflected by a low Karnofsky score, was strongly associated with poorer survival for various codings. For instance, the RR of death was estimated at 4.9 (95% CI, ; P.001) and the 1-year Kaplan-Meier survival rate was estimated at 48% for values of 40 or less (86% for values 40) (Figure 2B). This threshold was retained for further analysis because it allowed us to separate patients who remained at least partly autonomous (Karnofsky score, 40) from those who were bedridden (Karnofsky score, 40). Moreover, several medical conditions (eg, dementia, cardiac insufficiency, and personal history of stroke) appeared to be associated with poorer survival (Table 1). No variable reflecting extent or severity No. of Patients at Risk Figure 1. Overall survival distribution of the 170 patients with bullous pemphigoid initially treated with topical corticosteroids (testing sample). of BP, blood eosinophilia, or serum anti basement membrane zone antibodies appeared to be associated with overall survival (Table 2). INDEPENDENT PROGNOSTIC FACTORS FROM MULTIVARIATE ANALYSIS From multivariate analysis, only age and the Karnofsky score appeared independently predictive of overall survival. Patients older than 83 years had an elevated risk of death relative to younger patients (RR, 2.3; 95% CI, ; P=.02). Bedridden patients (Karnofsky score, 40) had a 4-fold increase in their risk of death (RR,4.1; 95% CI, ; P.001) compared with more autonomous patients (Karnofsky score, 40). As no significant interaction was found between these 2 variables (P=.57), patients older than 83 years and bedridden were 9.3 times (95% CI, ) more likely to die than younger, more autonomous patients. Female sex was not found to be independently predictive of survival because of its marked association with older age. Similarly, dementia, cardiac insufficiency, and history of stroke were not found to be independently predictive of survival because of their strong associations with patients general condition (for stroke and dementia) or age (for cardiac insufficiency). From the Cox proportional hazards regression model including the 2 independent prognostic factors of age and the Karnofsky score, predicted 1-year survival rates of BP patients were 90% (95% CI, 85%-96%) for patients 83 years and younger with a Karnofsky score of greater than 40 (prognostic category 1), 79% (95% CI, 69%- 90%) for patients older than 83 years with a Karnofsky score of greater than 40 (prognostic category 2), 65% (95% CI, 50%-86%) for patients 83 years or younger with a Karnofsky score of 40 or less (prognostic category 3), and 38% (95% CI, 26%-57%) for patients older than 83 years with a Karnofsky score of 40 or less (prognostic category 4), in close agreement with Kaplan-Meier 1-year survival estimates for these 4 categories (Figure 3). Moreover, R 2 was equal to 8, indicating that this model 693
4 Table 1. Baseline Characteristics at Initial Diagnosis of BP in Patients Initially Treated With Topical Corticosteroids According to Their Subsequent Survival Status at 1 Year* Characteristic Patients Dead Within 1 y (n = 45) 1-y Survivors (n = 125) RR (95% CI) of Death P Value Age, mean ± SD, y 85 ± 6 80 ± 10 7 (3-1.12).001 Sex Female 33 (73) 68 (54) 2.22 ( ).02 Male 12 (27) 57 (46) Karnofsky score, mean ± SD 45 ± ± ( ).001 High blood pressure Present 20 (44) 54 (43) 2 ( ).95 Absent 25 (56) 71 (57) Coronary disease Present 7 (16) 14 (11) 1.29 ( ).53 Absent 38 (84) 111 (89) Cardiac insufficiency Present 10 (22) 8 (6) 3.02 ( ).001 Absent 35 (78) 117 (94) Cardiac arrhythmia Present 5 (11) 18 (14) 0.75 (9-1.89).54 Absent 40 (89) 107 (86) Pulmary embolism Present 5 (11) 5 (4) 2.41 ( ).06 Absent 40 (89) 120 (96) Arteriosclerosis obliterans of the legs Present 3 (7) 5 (4) 1.30 (0-4.21).66 Absent 42 (93) 120 (96) Stroke Present 14 (31) 16 (13) 2.59 ( ).002 Absent 31 (69) 109 (87) Dementia Present 18 (40) 17 (14) 3.20 ( ).001 Absent 27 (60) 108 (86) Parkinson disease Present 5 (11) 8 (6) 1.60 (3-4.05).32 Absent 40 (89) 117 (94) Nervous breakdown Present 2 (4) 11 (9) 0.51 ( ).34 Absent 43 (96) 114 (91) Other neurological disease Present 1 (2) 5 (4) 0.59 (8-4.32).60 Absent 44 (98) 120 (96) Diverticulosis Present 4 (9) 13 (10) 7 ( ).80 Absent 41 (91) 112 (90) Cirrhosis Present 1 (2) 1 (1) 1.68 (3-2.20).60 Absent 44 (98) 124 (99) Gastric ulcer Present 2 (4) 6 (5) 0.91 (2-3.77).90 Absent 43 (96) 119 (95) Cholelithiasis Present 1 (2) 5 (4) 0 (8-4.38).61 Absent 44 (98) 120 (96) Chronic lung condition Present 2 (4) 12 (10) 5 ( ).26 Absent 43 (96) 113 (90) Cancer Present 3 (7) 11 (9) 0.73 (3-2.37).60 Absent 42 (93) 114 (91) Diabetes mellitus Present 4 (9) 7 (6) 1.32 (7-3.70).59 Absent 41 (91) 118 (94) Abbreviations: BP, bullous pemphigoid; CI, confidence interval; RR, relative risk. *The population included constitutes the testing sample. Unless otherwise indicated, data are expressed as number (percentage) of patients. Calculated by means of the Cox proportional hazards regression model (age and Karnofsky score) or log-rank test (all other characteristics). Indicates per year. Indicates per decrease in Karnofsky score in increments of
5 A B P <.001 P <.001 Age 83 y Age >83 y No. of Patients at Risk Age 83 y Age >83 y Karnofsky Score >40 Karnofsky Score 40 No. of Patients at Risk Karnofsky Score > Karnofsky Score Figure 2. Overall survival distributions of the 170 patients with bullous pemphigoid according to age ( 83 vs 83 years) (A) and Karnofsky score ( 40 vs 40) (B). Table 2. Baseline Characteristics of BP According to the Patients Subsequent Survival Status* BP Characteristic Patients Dead Within 1 y (n = 45) 1-y Survivors (n = 125) RR (95% CI) of Death P Value Delay since onset of disease, mean ± SD, d 89 ± ± (0.99-2).91 Pruritus Present 42 (93) 118 (94) 0.93 (8-2.99).90 Absent 3 (7) 7 (6) No. of new bullae daily, mean ± SD 26 ± ± 49 2 ( ).53 Extent of BP Extensive ( 10 new bullae daily) 22 (49) 71 (57).32 Moderate ( 10 new bullae daily) 23 (51) 54 (43) 1.34 ( ) Blood eosinophils, mean ± SD, cells/µl 1700 ± ± (0.99-3).29 Anti-BMZ antibodies Present 31 (78) 80 (71) 1.43 (9-3.01).34 Absent 9 (22) 33 (29) Abbreviations: BMZ, basement membrane zone; BP, bullous pemphigoid; CI, confidence interval; RR, relative risk. *The population included constitutes the testing sample. Unless otherwise indicated, data are expressed as number (percentage) of patients. From Cox model (delay since onset of disease, number of daily new bullae, blood eosinophils) or log-rank test (all other characteristics). Indicates RR per 7 days. Indicates RR per 10 daily new bullae. Indicates RR per 100 cells/µl. Not available in 5 patients who died within 1 year and 12 who were 1-year survivors. including age and the Karnofsky score offered a fairly good prediction of patients overall survival. EXTERNAL VALIDATION The findings in the testing sample were independently validated in patients from the 2 validation samples. Seventy-six patients (28 men and 48 women) with moderate BP (ie, 10 new bullae daily) were randomized to receive oral corticosteroids (prednisone) at the initial dosage of 0.5 mg/kg per day and constituted the first validation sample. Their mean age was 81±10 years (median age, 83 years) and their mean Karnofsky score was 66±24 (median score, 60). Their mean number of daily new blisters was 4±3 at baseline. The 1-year Kaplan- Meier overall survival rate of these patients was 70% (95% CI, 59%-80%). Kaplan-Meier survival distributions appeared clearly separated according to the 4 prognostic categories defined herein, and the ordering of these categories was essentially maintained. Kaplan-Meier 1-year survival rates of 90%, 70%, 67% and 35% for prognostic categories 1 to 4, respectively (Figure 4A), were in very close agreement with corresponding predicted 1-year survival rates obtained from the testing sample and well within their range of error. Moreover, R 2 was equal to 4, indicating fairly good prediction of overall survival from 695
6 Age 83 y, Karnofsky Score >40 Age >83 y, Karnofsky Score >40 Age 83 y, Karnofsky Score 40 Age >83 y, Karnofsky Score Figure 3. Overall survival distributions (observed and predicted) of the 170 patients with bullous pemphigoid according to joint levels of the 2 independent prognostic factors of age ( 83 vs 83 years) and Karnofsky score ( 40 vs 40). Data were obtained from the empirical cumulative hazard function estimated from the Cox proportional hazards regression model including age and Karnofsky score. A B Age 83 y, Karnofsky Score >40 Age >83 y, Karnofsky Score >40 Age 83 y, Karnofsky Score 40 Age >83 y, Karnofsky Score 40 Age 83 y, Karnofsky Score >40 Age 83 y, Karnofsky Score 40 Age >83 y, Karnofsky Score >40 Age >83 y, Karnofsky Score 40 Figure 4. Overall survival distributions of the patients with bullous pemphigoid who were initially treated with oral corticosteroids at starting dosages of 0.5 mg/kg per day (n=70) (A) or mg/kg per day (n=95) (B) according to joint level of the 2 independent prognostic factors of age ( 83 and 83 years) and Karnofsky score ( 40 and 40). the testing sample model. Moreover, upon fitting the same Cox model as in the testing sample, RR estimates were 3.0 for age greater than 83 years and 3.4 for a Karnofsky score of 40 or less, again in fairly close agreement with values obtained from the testing sample and well within their range of error. The second validation sample included 95 patients (32 men and 63 women) with extensive BP (ie, 10 new bullae daily) randomized to receive oral prednisone at a dosage of 1 mg/kg per day. Their mean age was 81±9 years (median age, 82 years), and their mean Karnofsky score was 63±24 (median score, 60). Their mean number of daily new blisters was 64±74 at baseline. Overall survival was worse than that of patients treated topically, with a 1-year Kaplan-Meier overall survival rate of 59% (95% CI, 49%-69%). Again, patients overall survival was 696
7 strongly influenced by their age and Karnofsky score, with perhaps a weaker influence of the latter than in the testing sample and first validation sample. The Kaplan- Meier 1-year survival rates were 84%, 44%, 53%, and 33% for prognostic categories 1 through 4, respectively (Figure 4B). COMMENT The main result of this study is that old age and poor general condition are the 2 major detrimental prognostic factors of BP. Indeed, patients older than 83 years and with a Karnofsky score of 40 or less had a more than 9-fold increase in their risk of dying during the first year of treatment relative to younger ( 83 years), more autonomous (Karnofsky score, 40) patients, and their predicted 1-year survival rate was only 38%, whereas that of younger, more autonomous patients was 90%. These results could be validated on 2 independent series of BP patients treated with regimens of medium- or high-dose oral corticosteroids. Survival predictions appeared particularly accurate in patients treated with medium-dose oral corticosteroids. Our results are consistent with those of Roujeau et al, 3 who also found older age and poor general condition to be associated with decreased overall survival. However, unlike those authors, we did not find female sex to be an independent detrimental prognostic factor of overall survival. Indeed, although female sex was separately predictive of decreased overall survival in the univariate analysis (RR, 2.2; 95% CI, ), it was not independently predictive of overall survival in the multivariate analysis (RR,1.2; 95% CI, -2.5) because of its strong associations with older age. Our results are also consistent with those of Rzany et al 12 regarding the detrimental prognostic role of older age. No factor reflecting BP extent or severity was shown to be related to prognosis. Although this series consisted of patients with various extents of cutaneous lesions (ranging from new bullae daily), no relationship was found between patients overall survival and their daily number of new bullae, whether it was coded as a continuous variable or dichotomized ( 10 or 10 new bullae daily). This result is in stark contrast with that of Roujeau et al, 3 who found that the overall survival of patients with moderate BP was significantly longer than that of patients with extensive BP. This discrepancy may be explained by the retrospective nature of the study by Roujeau et al 3 and the confounding effect of treatment. Indeed, in their study, many patients with moderate BP were treated with topical corticosteroids, whereas all patients with extensive BP were treated with high doses of oral corticosteroids, sometimes in association with immunosuppressive drugs. In contrast, our results, which are based on an accurate prospective assessment of BP extent, are not vulnerable to confounding by treatment and are in accordance with results from our group s previous controlled study of azathioprine sodium and plasmapheresis in addition to corticosteroids, in which no relationship was found between the initial extent of BP and overall survival. 30 Unfortunately, the daily number of new bullae was not available in the prognostic study by Rzany et al. 12 This prognostic study has 2 major strengths. First, to our knowledge, it is the first extensive prognostic study of BP based on a prospective design. Second, the confounding effect of treatment can be ruled out because all patients in the testing sample received identical initial treatment and dosages were modified according to a standardized protocol. As for potential limitations, a priori sample size computations were performed for the randomized clinical trial 11 on which this study was based but not for this prognostic study. However, an a posteriori computation based on the number of deaths observed in the testing sample was reassuring. Indeed, whereas this prognostic study had limited statistical power for detecting prognostic factors of moderate impact (eg, 60% power for a 2-sided log-rank test at the P.05 level relative to balanced dichotomous predictors with an RR of 2.0 for the detrimental prognostic category), it had high power for detecting stronger risk factors (eg, 80% and 97% power for a 2-sided log-rank test at the P.05 level relative to balanced dichotomous predictors, with respective RR values of 2.5 and 4.0 for the detrimental prognostic category). Overall, the results from this study indicate that BP prognosis is influenced by age and general condition but not by disease activity. These predictors are easy to use and should facilitate the management of BP. In particular, these results should prompt clinicians to be cautious in the treatment of older BP patients who are in poor general condition. 31,32 In our opinion, these patients should be treated with topical corticosteroids or with low doses of prednisone. Accepted for Publication: December 21, Author Affiliations: Departments of Dermatology and Biostatistics, Institut National de la Santé et de la Récherche Médicale U 519, University of Rouen, Rouen, France (Drs Joly, Benichou, and Hellot); Departments of Dermatology, University of Amiens, Amiens, France (Dr Lok); University Paris Ouest (Dr Saiag), University of Paris X (Drs Tancrede-Bohin and Chosidow), University of Paris V (Dr Gorin), University of Paris XIII (Dr Caux), University of Paris Saint Louis (Dr Prost), and University of Paris XII (Dr Roujeau), Paris, France; and Departments of Dermatology, University of Brest, Brest (Dr Sassolas), General Hospital of Valence, Valence (Dr Labeille), University of Bordeaux, Bordeaux (Dr Doutre), General Hospital of Saint-Germain, Saint-Germain (Dr Pauwels), General Hospital of Orleans, Orleans (Dr Estève), University of Dijon, Dijon (Dr Dutronc), General Hospital of Argenteuil, Argenteuil (Dr Sigal), General Hospital of Le Mans, Le Mans (Dr Maillard), and General Hospital of Colmar, Colmar (Dr Guillaume), France. Correspondence: Pascal Joly, MD, PhD, Clinique Dermatologique, Hôpital Charles Nicolle, 1, rue de Germont, Rouen CEDEX, France Group Members: The following investigators also participated in this study: Catherine Picard, MD, Paris, France; Brigitte Dreno, MD, PhD, Nantes, France; Emmanuel Delaporte, MD, PhD, Lille, France; Loïc Vaillant, MD, PhD, Tours, France; Michel D Incan, MD, PhD, 697
8 Clermont Ferrand, France; Patrice Plantin, MD, Quimper, France; Christophe Bedane, MD, PhD, Limoges, France; and Philippe Bernard, MD, PhD, Reimes, France. Funding/Support: This study was supported by research grants from Rouen University Hospital, Rouen, France, and the French Society of Dermatology, Paris, France. Acknowledgment: The software used to estimate the multivariate coefficient of determination (R 2 ) was kindly provided by John O Quigley, PhD, Department of Biostatistics, Institut Curie, Paris. REFERENCES 1. Bernard P, Vaillant L, Labeille B, et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Arch Dermatol. 1995;131: Zillikens D, Wever S, Roth A, Hashimoto T, Brocker EB. Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany. Arch Dermatol. 1995;131: Roujeau JC, Lok C, Bastuji-Garin S, Mhalla S, Enginger V, Bernard P. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol. 1998;134: Bernard P, Bedane C, Bonnetblanc JM. Anti-BP180 autoantibodies as a marker of poor prognosis in bullous pemphigoid: a cohort analysis of 94 elderly patients. Br J Dermatol. 1997;136: Milligan A, Hutchinson PE. The use of chlorambucil in the treatment of bullous pemphigoid. J Am Acad Dermatol. 1990;22: Vaillant L, Bernard P, Joly P, et al; French Bullous Study Group. Evaluation of clinical criteria for diagnosis of bullous pemphigoid. Arch Dermatol. 1998; 134: Fine JD. Management of acquired bullous skin diseases. N Engl J Med. 1995;333: Bernard P, Enginger V, Venot J, Bedane C, Bonnetblanc JM. Survival prognosis in pemphigoid: a cohort analysis of 78 patients. Ann Dermatol Venereol. 1995; 122: Venning VA, Wojnarowska F. Lack of predictive factors for the clinical course of bullous pemphigoid. J Am Acad Dermatol. 1992;26: Savin JA. The events leading to the death of patients with pemphigus and pemphigoid. Br J Dermatol. 1979;101: Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346: Rzany B, Partscht K, Jung M, et al. Risk factors for lethal outcome in patients with bullous pemphigoid. Arch Dermatol. 2002;138: Burton JL, Harman RR, Peachey RD, Warin RP. Azathioprine plus prednisone in the treatment of pemphigoid. BMJ. 1978;2: Greaves MW, Burton JL, Marks J, Dawber RP. Azathioprine in the treatment of bullous pemphigoid. BMJ. 1971;1: Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol. 1995;131: Krain LS, Landau JW, Newcomer VD. Cyclophosphamide in the treatment of pemphigus vulgaris and bullous pemphigoid. Arch Dermatol. 1972;106: Thivolet J, Barthelemy H, Rigot-Muller G, Bendelac A. Effects of cyclosporin on bullous pemphigoid and pemphigus. Lancet. 1985;1: Paul MA, Jorizzo JL, Fleischer AB, White WL. Low-dose methotrexate treatment in elderly patients with bullous pemphigoid. J Am Acad Dermatol. 1994;31: Bohm M, Beissert S, Schwarz T, Metze D, Luger T. Bullous pemphigoid treated with mycophenolate mofetil. Lancet. 1997;349: Grundmann-Kollmann M, Korting HC, Behrens S, et al. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol. 1999;40: Khumalo N, Kirtschig G, Middleton P, Hollis S, Wojnarowska F, Murell D. Interventions for bullous pemphigoid. Cochrane Database Syst Rev. 2003:CD Mutasim DF. Treatment considerations while awaiting the ideal bullous pemphigoid trial. Arch Dermatol. 2002;138: Stern RS. Bullous pemphigoid therapy: think globally, act locally. N Engl J Med. 2002;346: Courville P, Kupfer I, Gilbert D, Thomine E, Metayer J, Joly P. Evaluation of histological criteria for bullous pemphigoid: correlation with antigens recognized by immunoblotting of anti-epidermal autoantibodies. Ann Pathol. 2000;20: Gammon WR, Kowalewski C, Chorzelski TP, Kumar V, Briggaman RA, Beutner EH. Direct immunofluorescence studies of sodium chloride separated skin in the differential diagnosis of bullous pemphigoid and epidermolysis bullosa acquisita. J Am Acad Dermatol. 1990;22: Joly P, Gilbert D, Thomine E, et al. Relationship between the in vivo localization and the immunoblotting pattern of anti basement membrane zone antibodies in patients with bullous pemphigoid. Arch Dermatol. 1997;133: Crooks V, Waller S, Smith T, Hahn TJ. The use of the Karnofsky Performance Scale in determining outcomes and risk in geriatric outpatients. J Gerontol. 1991; 46:M139-M Arjas E. A graphical method for assessing goodness of fit in Cox s proportional hazards model. J Am Stat Assoc. 1988;83: Xu R, O Quigley JA. R 2 type measure of dependence for proportional hazards models. J Nonparametric Stat. 1999;12: Guillaume JC, Vaillant L, Bernard P, et al. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol. 1993;129: Westerhof W. Treatment of bullous pemphigoid with topical clobetasol propionate. J Am Acad Dermatol. 1989;20: Thomas TP. The complications of systemic corticosteroid therapy in the elderly: a retrospective study. Gerontology. 1984;30:
COMPARISON OF ORAL AND TOPICAL CORTICOSTEROIDS IN PATIENTS WITH BULLOUS PEMPHIGOID
COMPARISON OF AND CORTICOSTEROIDS IN PATIENTS WITH BULLOUS PEMPHIGOID A COMPARISON OF AND CORTICOSTEROIDS IN PATIENTS WITH BULLOUS PEMPHIGOID PASCAL JOLY, M.D., PH.D., JEAN-CLAUDE ROUJEAU, M.D., JACQUES
More informationSTUDY. High Risk of Death in Elderly Patients With Extensive Bullous Pemphigoid
STUDY High Risk of Death in Elderly Patients With Extensive Bullous Pemphigoid Jean-Claude Roujeau, MD; Catherine Lok, MD; Sylvie Bastuji-Garin, MD; Sami Mhalla, MD; Véronique Enginger, MD; Philippe Bernard,
More informationSTUDY. A Comparison of Oral Methylprednisolone Plus Azathioprine or Mycophenolate Mofetil for the Treatment of Bullous Pemphigoid
STUDY A Comparison of Oral Methylprednisolone Plus Azathioprine or Mycophenolate Mofetil for the Treatment of Bullous Pemphigoid Stefan Beissert, MD; Thomas Werfel, MD; Uta Frieling, MD; Markus Böhm, MD;
More informationGuidelines for the management of bullous pemphigoid
British Journal of Dermatology 2002; 147: 214 221. GUIDELINES Guidelines for the management of bullous pemphigoid F.WOJNAROWSKA, G.KIRTSCHIG, A.S.HIGHET,* V.A.VENNING AND N.P.KHUMALO Department of Dermatology,
More informationRisk Factors for Bullous Pemphigoid in the Elderly: A Prospective Case Control Study
ORIGINAL ARTICLE in the Elderly: A Prospective Case Control Study Sylvie Bastuji-Garin 1,2, Pascal Joly 3, Pauline Lemordant 4, Agnès Sparsa 5, Christophe Bedane 5, Emmanuel Delaporte 6, Jean-Claude Roujeau
More informationRESEARCH. Bullous pemphigoid and pemphigus vulgaris incidence and mortality in the UK: population based cohort study
and pemphigus vulgaris incidence and mortality in the UK: population based cohort study S M Langan, research fellow, 1 LSmeeth,professorofclinicalepidemiology, 2 R Hubbard, professor of respiratory epidemiology,
More informationA case of bullous pemphigoid following pemphigus foliaceus
#2228 A case of bullous pemphigoid following pemphigus foliaceus Priyanka Vedak MD 1, Danielle Levine MD 1,3, Lyn Duncan MD 2,3, Hensin Tsao 1,3, Daniela Kroshinsky MD MPH 1,3 1. Department of Dermatology,
More informationErythema gyratumrepens-like eruption in a patient with epidermolysisbullosaacquisita associated with ulcerative colitis
Erythema gyratumrepens-like eruption in a patient with epidermolysisbullosaacquisita associated with ulcerative colitis A. España C. Sitaru* M. Pretel L. Aguado J. Jimenez# Department of Dermatology, University
More informationThe value of the pragmatic-explanatory continuum indicator summary wheel in an ongoing study: the bullous pemphigoid steroids and tetracyclines study
Bratton et al. Trials 2012, 13:50 TRIALS METHODOLOGY Open Access The value of the pragmatic-explanatory continuum indicator summary wheel in an ongoing study: the bullous pemphigoid steroids and tetracyclines
More informationPrognostic factors for mortality in patients with bullous pemphigoid: a meta-analysis
DOI 10.1007/s00403-017-1736-1 ORIGINAL PAPER Prognostic factors for mortality in patients with bullous pemphigoid: a meta-analysis Yi Di Liu 1 Yan Hong Wang 2 Yi Cong Ye 3 Wen Ling Zhao 1 Li Li 1 Received:
More informationEpidermolysis Bullosa Acquisita: A Retrospective Clinical Analysis of 30 Cases
Acta Derm Venereol 2011 Epub ahead of print CLINICAL REPORT Epidermolysis Bullosa Acquisita: A Retrospective Clinical Analysis of 30 Cases Jong Hoon Kim 1, Yeon Hee Kim 2 and Soo-Chan Kim 1 1 Department
More informationEVATEL Study. Remote follow-up of patients implanted with an ICD The prospective randomized EVATEL study
EVATEL Study Remote follow-up of patients implanted with an ICD The prospective randomized EVATEL study Philippe Mabo, Pascal Defaye, Nicolas Sadoul, Jean Marc Davy, Jean-Claude Deharo, Salem Kacet, Eric
More informationIntroduction to Pemphigoid: Spectrum of Disease & Treatment
Introduction to Pemphigoid: Spectrum of Disease & Treatment A Razzaque Ahmed, MD Center for Blistering Diseases Boston, MA A.Razzaque.Ahmed@tufts.edu centerforblisteringdiseases.com SPECTRUM OF PEMPHIGOID
More informationIf a drug trigger is suspected, stop the offending drug as this may reduce the risk of relapse.
There is so much we don't know in medicine that could make a difference, and often we focus on the big things, and the little things get forgotten. To highlight some smaller but important issues, we've
More informationFUnctional Testing Underlying REvascularization The FUTURE trial
FUnctional Testing Underlying REvascularization The FUTURE trial Gilles Rioufol, François Roubille, Thibault Perret, Pascal Motreff, Denis Angoulvant, Yves Cottin, Ludovic Meunier,Nathan Mewton, Michel
More informationTreatment with steroids and immunosuppressants
Treatment with steroids and immunosuppressants Donna Culton, MD, PhD University of North Carolina IPPF 2017 Annual Patient Conference Newport Beach, CA September 16, 2017 Factors that will influence therapy
More informationAutoimmune Diseases with Oral Manifestations
Autoimmune Diseases with Oral Manifestations Martin S. Greenberg DDS, FDS RCSEd Professor Emeritus Department of Oral Medicine University of Pennsylvania Disclosure Statement I have no actual or potential
More informationBullous pemphigoid appearing as superficial tissue necrosis after irradiation of the breast: Case history and definitive review of the literature
CASE REPORTS Bullous pemphigoid appearing as superficial tissue necrosis after irradiation of the breast: Case history and definitive review of the literature Mark Trombetta 1, 4, Kathleen Erb 2, 4, Vijay
More informationDepartment of Dermatology, Christian Medical College and Hospital, Ludhiana, Punjab, India.
Bullous pemphigoid mimicking granulomatous inflammation Abhilasha Williams, Emy Abi Thomas. Department of Dermatology, Christian Medical College and Hospital, Ludhiana, Punjab, India. Egyptian Dermatology
More informationPharmacologyonline 1: 1-6 (2010) Case Report Ravishankar and Hiremath CIPROFLOXACIN INDUCED BULLOUS PEMPHIGOID: A CASE REPORT
CIPROFLOXACIN INDUCED BULLOUS PEMPHIGOID: A CASE REPORT Ravishankar AC 1*, Hiremath SV 1 1 Dept of Pharmacology and Pharmacotherapeutics, JN Medical College, Belgaum, India. Summary Bullous pemphigoid
More informationSYNOPSIS (PROTOCOL WX17796)
TITLE OF THE STUDY A prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter, 52-week trial to assess the efficacy and safety of adjunct MMF to achieve remission with reduced
More informationA Single Cycle of Rituximab for the Treatment of Severe Pemphigus
T h e n e w e ng l a nd j o u r na l o f m e dic i n e original article A Single Cycle of Rituximab for the Treatment of Severe Pemphigus Pascal Joly, M.D., Ph.D., Hugo Mouquet, Ph.D., Jean-Claude Roujeau,
More informationKDIGO GN Guideline update Evidence summary. Steroid-sensitive nephrotic syndrome. Corticosteroid therapy for nephrotic syndrome in children
KDIGO GN Guideline update Evidence summary Steroid-sensitive nephrotic syndrome Corticosteroid therapy for nephrotic syndrome in children PICO question In children (aged 3 to 18 years of age) with steroid-sensitive
More informationComment on Association of bullous pemphigoid with malignancy: A systematic review and meta-analysis
Accepted Manuscript Comment on Association of bullous pemphigoid with malignancy: A systematic review and meta-analysis Maglie Roberto, MD, Antiga Emiliano, MD, PhD, Caproni Marzia, MD, PhD PII: S0190-9622(17)32812-8
More informationTitle. CitationBritish Journal of Dermatology, 155(5): Issue Date Doc URL. Rights. Type. File Information
Title Childhood epidermolysis bullosa acquisita with autoa collagen : case report and review of the literature Author(s)Mayuzumi, M.; Akiyama, M.; Nishie, W.; Ukae, S.; Abe CitationBritish Journal of Dermatology,
More informationBullous Pemphigoid with Lymphocytic Colitis: A Case Report and Short Literature Review
Dermatol Ther (Heidelb) (2016) 6:437 441 DOI 10.1007/s13555-016-0135-4 CASE REPORT Bullous Pemphigoid with Lymphocytic Colitis: A Case Report and Short Literature Review Alexandra Sperl. Johann W. Bauer.
More informationTo Correlate Clinical Diagnosis with Histopathology and DIF Pattern of Autoimmune Based Vesiculobullous Disorders In A Tertiary Teaching Hospital
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 17, Issue 7 Ver. 2 (July. 2018), PP 01-06 www.iosrjournals.org To Correlate Clinical Diagnosis with Histopathology
More informationORIGINAL CONTRIBUTION. Treatment of Myasthenia Gravis Exacerbation With Intravenous Immunoglobulin
ORIGINAL CONTRIBUTION Treatment of Myasthenia Gravis Exacerbation With Intravenous Immunoglobulin A Randomized Double-blind Clinical Trial Philippe Gajdos, MD; Christine Tranchant, MD; Bernard Clair, MD;
More informationSerologic Markers CONVENTIONAL ANTIBODIES ANTIBODIES UNCONVENTIONAL. AIH Type I
Autoimmune Hepatitis By Thomas Frazier Objective What we need to know about AIH Diagnosis Treatment Difficulties in both Liver transplantation concerns AASLD Guidelines: Hepatology. 2010 Jun;51(6):2193-213.
More informationLiver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995
Liver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995 Steven H. Belle, Kimberly C. Beringer, and Katherine M. Detre T he Scientific Liver Transplant Registry (LTR) was established
More informationA cross-sectional study of clinical, histopathological and direct immmunofluorescence diagnosis in autoimmune bullous diseases
Original Article A cross-sectional study of clinical, histopathological and direct immmunofluorescence diagnosis in autoimmune bullous diseases Anchal Jindal, MD 1 Rushikesh Shah, MBBS 2 Neela Patel, MD
More informationEpidermolysis Bullosa Acquisita
Introduction Epidermolysis Bullosa Acquisita Pages with reference to book, From 192 To 194 Nasser Rashid Dar ( Departments of Dermatology, Combined Military Hospital, Peshawar. ) Ahsan Hameed, Ashfaq Ahmad
More informationatorvastatin 10mg, amlodipine 5mg and dilitazem 60mg. He had unexplained iron deficiency anaemia (hemoglobin-8.4gm/dl, ferritin- 4.73ng/ml, total iron
Pemphigus herpetiformis : A rare clinical variant of pemphigus Shrestha P 1, Tajhya RB 2, Pokharel A 3 1,2 Consultant Dermatologist, Department of Dermatology, Vayodha Hospital Pvt. Ltd, Balkhu, Kathmandu,
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationThe Long-term Prognosis of Delirium
The Long-term Prognosis of Jane McCusker, MD, DrPH, Professor, Epidemiology and Biostatistics, McGill University; Head, Clinical Epidemiology and Community Studies, St. Mary s Hospital, Montreal, QC. Nine
More informationPBC features and management in the era of UDCA and Budesonide
PBC features and management in the era of UDCA and Budesonide Raoul Poupon, MD Université P&M Curie, AP-Hôpitaux de Paris, Inserm, Paris, France The changing pattern of PBC Over the last 2 decades: More
More informationChapter 4: Steroid-resistant nephrotic syndrome in children Kidney International Supplements (2012) 2, ; doi: /kisup.2012.
http://www.kidney-international.org & 2012 KDIGO Chapter 4: Steroid-resistant nephrotic syndrome in children Kidney International Supplements (2012) 2, 172 176; doi:10.1038/kisup.2012.17 INTRODUCTION This
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationDepartment of Dermatology, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo , Japan 2
Dermatology Research and Practice Volume 2010, Article ID 931340, 5 pages doi:10.1155/2010/931340 Case Report Paraneoplastic Pemphigus Presenting as Mild Cutaneous Features of Pemphigus Foliaceus and Lichenoid
More informationImpaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events
Diabetes Care Publish Ahead of Print, published online May 28, 2008 Chronotropic response in patients with diabetes Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts
More informationChronic Eczematous Eruptions of the Elderly Are Associated with Chronic Exposure to Calcium Channel Blockers: Results from a Case Control Study
ORIGINAL ARTICLE See related commentary on pg 2709 Chronic Eczematous Eruptions of the Elderly Are Associated with Chronic Exposure to Calcium Channel Blockers: Results from a Case Control Study Pascal
More informationThe benefit of treatment with -blockers in heart failure is
Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial Philippe Lechat, MD, PhD; Jean-Sébastien Hulot, MD; Sylvie Escolano, MD, PhD; Alain Mallet,
More informationComparison of the narrow band UVB versus systemic corticosteroids in the treatment of lichen planus: A randomized clinical trial
Received: 10.7.2011 Accepted: 5.12.2011 Original Article Comparison of the narrow band UVB versus systemic corticosteroids in the treatment of lichen planus: A randomized clinical trial Fariba Iraji, 1
More informationEgyptian Dermatology Online Journal Vol. 8 No 2: 6, December Yasmeen J Bhat*, Iffat Hasan*, Atiya Yaseen*, Hina Altaf*, Shylla Mir**
Pemphigoid gestationis in a multigravida Yasmeen J Bhat*, Iffat Hasan*, Atiya Yaseen*, Hina Altaf*, Shylla Mir** * Department of Dermatology, STD & Leprosy; Government Medical College, Srinagar ** Department
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Membranous nephropathy role of steroids GUIDELINES
Membranous nephropathy role of steroids Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES There is currently no data to support the use of short-term courses of
More informationElements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Chronic lymphocytic leukaemia 1 Chronic lymphocytic leukemia (CLL) is a condition characterized by a progressive accumulation
More informationThe incidence of internal malignancies in autoimmune bullous diseases
Tokai J Exp Clin Med., Vol. 32, No. 1, pp. 42-47, 2007 The incidence of internal malignancies in autoimmune bullous diseases Kenichi IWASHITA, Takashi MATSUYAMA, Emiko AKASAKA, Kimihiko MIZUTANI, Kozo
More informationPredictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
More informationFrench Networks for Sarcoma and GIST. O Mir, JY Blay
French Networks for Sarcoma and GIST O Mir, JY Blay Introduction Since 2009 a network of 26 reference multidisciplinary centers aiming to improve the quality of care for sarcoma patients in France was
More informationKBP2000-articles. [Five year survival for lung cancer patients managed in general hospitals]
1. Rev Mal Respir. 2009 Jan;26(1):37-44. KBP2000-articles [Five year survival for lung cancer patients managed in general hospitals] Grivaux M, Zureik M, Marsal L, Asselain B, Peureux M, Chavaillon JM,
More informationTo cite this version: HAL Id: hal https://hal-univ-rennes1.archives-ouvertes.fr/hal
Cell-of-Origin (COO) Classification, BCL2 and MYC Expression Associated Outcome in Younger Patients Treated By RCHOP Front-Line Therapy Versus Intensive Regimen Followed By Autologous Transplant for De
More informationArbolishvili GN, Mareev VY Institute of Clinical Cardiology, Moscow, Russia
THE VALUE OF 24 H HEART RATE VARIABILITY IN PREDICTING THE MODE OF DEATH IN PATIENTS WITH HEART FAILURE AND SYSTOLIC DYSFUNCTION IN BETA-BLOCKING BLOCKING ERA Arbolishvili GN, Mareev VY Institute of Clinical
More informationInteresting Case Series. Linear IgA Bullous Dermatosis
Interesting Case Series Linear IgA Bullous Dermatosis Sean Chen, BA, a Peter Mattei, MD, a Max Fischer, MD, MPH, a Joshua D. Gay, PA-C, b Stephen M. Milner, MBBS, BDS, FRCS (Ed), FACS, b and Leigh Ann
More informationDr Saleem Taibjee. Consultant Dermatologist & Dermatopathologist
Dr Saleem Taibjee saleem.taibjee@dchft.nhs.uk Consultant Dermatologist & Dermatopathologist Case S14-10797 and S15-4023 F50. Previous blistering, now marked milia on dorsum of hands. 4mm punch biopsy The
More informationCASE REPORT. doi: /iwj.12670
International Wound Journal ISSN 1742-4801 CASE REPORT Development of bullous pemphigoid during the haemodialysis of a young man: case report and literature survey Katarzyna Osipowicz, Agnieszka Kalinska-Bienias,
More informationClinicopathological correlation of blistering diseases of skin
Bangladesh Med Res Counc Bull 2008; 34: 48-53 Copyright 2008 by Bangladesh Medical Research Council Clinicopathological correlation of blistering diseases of skin A.K.M. Nurul Kabir 1, Mohammed Kamal 1
More informationClearance in vulvar lichen sclerosus: a realistic treatment endpoint or a chimera?
DOI: 10.1111/jdv.14516 JEADV SHORT REPORT Clearance in vulvar lichen sclerosus: a realistic treatment endpoint or a chimera? A. Borghi,* A. Virgili, S. Minghetti, G. Toni, M. Corazza Dipartimento di Scienze
More informationNon-Compliance with Guidelines: Motivations and Consequences in a case study. The ischemic stroke management
Non-Compliance with Guidelines: Motivations and Consequences in a case study The ischemic stroke management Silvana QUAGLINI, Paolo CICCARESE, Giuseppe MICIELI*, Anna CAVALLINI* Dipartimento di Informatica
More informationSkin cancers in patients treated with immunomodulating drugs. Manuelle Viguier, MD, PhD Dermatology department Saint-Louis Hospital Paris, France
Skin cancers in patients treated with immunomodulating drugs Manuelle Viguier, MD, PhD Dermatology department Saint-Louis Hospital Paris, France Immunomodulating drugs used in Methotrexate Mycophenolate
More informationSTUDY. Prognostic Factors of Paraneoplastic Pemphigus
ONLINE FIRST STUDY Prognostic Factors of Paraneoplastic Pemphigus Sandy Leger, MD; Damien Picard, MD, PhD; Saskia Ingen-Housz-Oro, MD; Jean-Philippe Arnault, MD; François Aubin, MD, PhD; Francis Carsuzaa,
More informationSummary BREAST CANCER - Early Stage Breast Cancer... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 BREAST CANCER - Early Stage Breast Cancer... 3 Large data analysis reveals similar survival outcomes with sequential
More informationSurgical Margins in Cutaneous Melanoma (2 cm Versus 5 cm for Lesions Measuring Less Than 2.1-mm Thick)
1941 Surgical Margins in Cutaneous Melanoma (2 cm Versus 5 cm for Lesions Measuring Less Than 2.1-mm Thick) Long-Term Results of a Large European Multicentric Phase III Study David Khayat, M.D., Ph.D.
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationMucous membrane pemphigoid in a patient with hypertension treated with atenolol: a case report
Kanjanabuch et al. Journal of Medical Case Reports 2012, 6:373 JOURNAL OF MEDICAL CASE REPORTS CASE REPORT Open Access Mucous membrane pemphigoid in a patient with hypertension treated with atenolol: a
More informationMandana Nikpour 1,2, Murray B Urowitz 1*, Dominique Ibanez 1, Paula J Harvey 3 and Dafna D Gladman 1. Abstract
RESEARCH ARTICLE Open Access Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective
More informationPemphigus in younger age group in Bangladeshi population
ORIGINAL ARTICLE in younger age group in Bangladeshi population Abdul Wahab 1, MD, Lubna Khondker 1, MD, Jamal Uddin 1, MD, Ishrat Bhuiyan 2, MD Shirajul Islam Khan 3, MD, Zafrul Islam 1, MD, Rahmat Ali
More informationKlinik und Diagnostik bullöser Autoimmundermatosen Wenn die Schleimhaut nicht mehr heilen will
Klinik und Diagnostik bullöser Autoimmundermatosen Wenn die Schleimhaut nicht mehr heilen will Ana Luiza Lima, Detlef Zillikens, Enno Schmidt Literatur Leserservice zm Nr. 08/2016, S. 72-84 Ahmed, A.R.,
More informationFUJI study: Follow-Up of Jevtana in real life
Pharmacologie médicale Bordeaux PharmacoEpi CIC Bordeaux CIC1401 FUJI study: Follow-Up of Jevtana in real life French retrospective and protective multicenter observational study describing the survival,
More informationالسكري للداء مرافقة فقاعات diabeticorum= Bullosis
1 / 6 Bullosis diabeticorum Bullous disease of diabetes (bullosis diabeticorum) is a distinct, spontaneous, noninflammatory, blistering condition of acral skin unique to patients with diabetes mellitus.
More informationTitle: Real-life use of inhaled corticosteroids in COPD patients vs. GOLD proposals: a paradigm shift in GOLD 2011?
ERJ Express. Published on October 31, 2013 as doi: 10.1183/09031936.00162313 Letter to the Editor Title: Real-life use of inhaled corticosteroids in COPD patients vs. GOLD proposals: a paradigm shift in
More informationBK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy
BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent
More informationHIV/AIDS CLINICAL CARE QUALITY MANAGEMENT CHART REVIEW CHARACTERISTICS OF PATIENTS FACTORS ASSOCIATED WITH IMPROVED IMMUNOLOGIC STATUS
HIV/AIDS CLINICAL CARE QUALITY MANAGEMENT CHART REVIEW CHARACTERISTICS OF PATIENTS WITH LOW CD4 COUNTS IN 2008 AND FACTORS ASSOCIATED WITH IMPROVED IMMUNOLOGIC STATUS FROM 2004 THROUGH 2008 For the Boston
More informationResponse. Philippe Saiag, 1,2 Philippe Aegerter, 3,4,5 Mathieu Boniol 6, Boulogne-Billancourt, France.
Saiag, Philippe and Aegerter, Philippe and Boniol, Mathieu (2016) Response. Journal of the National Cancer Institute, 108 (4). ISSN 0027-8874, http://dx.doi.org/10.1093/jnci/djw015 This version is available
More informationPemphigus foliaceus: a clinical study of 32 cases in Hong Kong 32
H.K. Dermatol. Venereol. Bull. (2004) 12, 126-132 Original Article Pemphigus foliaceus: a clinical study of 32 cases in Hong Kong 32 This is a cross-sectional, retrospective study of 32 Hong Kong Chinese
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Dupixent) Reference Number: CP.HNMC.208 Effective Date: 04.11.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/188/20915 holds various files of this Leiden University dissertation. Author: Flinterman, Linda Elisabeth Title: Risk factors for a first and recurrent venous
More informationORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults
ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen
More informationChapter 6: Transplantation
Chapter 6: Transplantation Introduction During calendar year 2012, 17,305 kidney transplants, including kidney-alone and kidney plus at least one additional organ, were performed in the United States.
More informationSKIN CANCER AFTER HSCT
SKIN CANCER AFTER HSCT David Rice, PhD, MSN, RN, NP, NEA-BC Director, Education, Evidence-based Practice and Research City of Hope National Medical Center HOW THE EXPERTS TREAT HEMATOLOGIC MALIGNANCIES
More informationClinical spectrum and therapeutic approach in pemphigus vulgaris
Clinical spectrum and therapeutic approach in pemphigus vulgaris Michael Hertl Department of Dermatology and Allergology Philipps University, Marburg, Germany F125: Bullous Diseases: Diagnostic and Management
More informationRituximab in refractory autoimmune bullous diseases
Clinical dermatology Review article doi: 10.1111/j.1365-2230.2006.02151.x Rituximab in refractory autoimmune bullous diseases E. Schmidt, N. Hunzelmann,* D. Zillikens, E.-B. Bröcker and M. Goebeler Departments
More informationMelanoma-Back to Basics I Thought I Knew Ya! Paul K. Shitabata, M.D. Dermatopathologist APMG
Melanoma-Back to Basics I Thought I Knew Ya! Paul K. Shitabata, M.D. Dermatopathologist APMG At tumor board, a surgeon insists that all level II melanomas are invasive since they have broken through the
More informationPoor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas
10 The Open Otorhinolaryngology Journal, 2011, 5, 10-14 Open Access Poor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas Kevin C. Huoh and Steven J. Wang * Head and Neck Surgery and Oncology,
More informationB. Autoimmune blistering diseases
Go Back to the Top To Order, Visit the Purchasing Page for Details formation immediately above the basal layer. The dermal papillae, which are covered by basal cells in the single layer that is left in
More informationTitle: Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death
Author's response to reviews Title: Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death Authors: Romuald Le Scodan (lescodan@crh1.org)
More informationGSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationRare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital
E-Da Medical Journal 20;():-5 Original Article Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital Wei-Ting Kuo, I-Wei Chang2, Kevin Lu, Hua-Pin Wang, Tsan-Jung u, Victor C.
More informationOriginal Contribution
Direct Immunofluorescence Test of Skin Biopsy Samples Results of 204 Cases Kabir AN, 1 Das RK, 2 Kamal M 3 Direct immunofluorescence (DIF) test of skin and renal biopsy specimens is being done on regular
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION Prognostic Role of Echocardiography Among Patients With Acute Pulmonary Embolism and a Systolic Arterial Pressure of 90 mm Hg or Higher Nils Kucher, MD; Elisa Rossi, BS; Marisa De
More informationExercise treadmill testing is frequently used in clinical practice to
Preventive Cardiology FEATURE Case Report 55 Commentary 59 Exercise capacity on treadmill predicts future cardiac events Pamela N. Peterson, MD, MSPH 1-3 David J. Magid, MD, MPH 3 P. Michael Ho, MD, PhD
More informationCan We Predict Relapses in Children with Idiopathic Steroid-Sensitive Nephrotic Syndrome?
JOURNAL OF TROPICAL PEDIATRICS, VOL. 59, NO. 5, 2013 Can We Predict Relapses in Children with Idiopathic Steroid-Sensitive Nephrotic Syndrome? by Om P. Mishra, 1 Abhishek Abhinay, 1 Rabindra N. Mishra,
More informationPEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL)
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf)
More informationDevelopment and ini.al valida.on of a prognos.c nomogram for ambulatory pa.ents with advanced cancer
Session: What Does the Future Hold? Prognos7ca7on in Advanced Cancer and Clinical Decision Making Development and ini.al valida.on of a prognos.c nomogram for ambulatory pa.ents with advanced cancer Paiva
More informationLung Cancer Risk Associated With New Solid Nodules in the National Lung Screening Trial
Cardiopulmonary Imaging Original Research Pinsky et al. Lung Cancer Risk Associated With New Nodules Cardiopulmonary Imaging Original Research Paul F. Pinsky 1 David S. Gierada 2 P. Hrudaya Nath 3 Reginald
More informationChapter 56 Bullous Pemphigoid
Chapter 56 Bullous Pemphigoid Donna A. Culton, Zhi Liu, & Luis A. Diaz REFERENCES 1. Lever WF: Pemphigus. Medicine (Baltimore) 32(1):1, 1953 2. Beutner EH et al: Autoantibodies in pemphigus vulgaris: Response
More informationPatient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival
MOLECULAR AND CLINICAL ONCOLOGY 7: 1083-1088, 2017 Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival FARUK TAS
More informationFaiez Zannad, MD, PhD, Nancy
1 Biotargets, drug discovery and therapeutic innovation. How French clinical networks can accelerate the discovery of new treatments in the field of cardiovascular and metabolic diseases? Faiez Zannad,
More informationAlcoholic Hepatitis: Management Options
Alcoholic Hepatitis: Management Options Paul J. Thuluvath, MD. FRCP Institute of Digestive Health & Liver Diseases, Mercy Medical Center, Baltimore Professor of Surgery & Medicine, Georgetown University,
More informationVulval dermatoses. Dr Fiona Lewis, Consultant Dermatologist St John s Institute of Dermatology, London & Heatherwood & Wexham Park Hospital, Slough
Vulval dermatoses Dr Fiona Lewis, Consultant Dermatologist St John s Institute of Dermatology, London & Heatherwood & Wexham Park Hospital, Slough Pigmentation Vulvodynia Ulcers Genetic Pruritus VULVAL
More informationResearch Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy
SAGE-Hindawi Access to Research Lung Cancer International Volume 2011, Article ID 152125, 4 pages doi:10.4061/2011/152125 Research Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients:
More information